Sodium Bicarbonate manufacturers & suppliers

Sodium Bicarbonate

Form: Intravenous (IV) Injection

Strength: 8.4% (1 mEq/mL)

Reference Brands: Sodium Bicarbonate Injection

Category: Critical Care

Sodium Bicarbonate is an essential alkalinizing agent used in emergency and critical care to treat metabolic acidosis, cardiac arrest, hyperkalemia, and certain drug overdoses. It is most commonly administered as an IV solution in 4.2% or 8.4% concentrations. Key brands include Pfizer, Fresenius Kabi, Hospira, and B. Braun, with available formats including vials, ampoules, and prefilled syringes. Sodium Bicarbonate IV is a life-saving hospital medicine, especially in ICUs and emergency departments. Pharma B2B platforms offer reliable, large-scale procurement of Sodium Bicarbonate solutions, supporting continuous supply for healthcare institutions across the US, EU, and other regulated global markets.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Glucagon

Strength: 1 mg lyophilized powder for reconstitution (IM/SC/IV)

Form: Intramuscular (IM), Subcutaneous (SC), and Intravenous (IV) injection

Reference Brands: Glucagen®, Gvoke®,Baqsimi®(US); Glucagen® Hypokit(EU)

View Details
Insulin (Iv)

Strength: 100 units/mL (U-100) in 10 mL vials

Form: Intravenous (IV) solution

Reference Brands: Humulin® R, Novolin® R(US); Actrapid®, Humulin® R, Insuman® Rapid(EU)

View Details
Flumazenil

Strength: 0.1 mg/mL in 5 mL or 10 mL vials

Form: Intravenous (IV) injection

Reference Brands: Romazicon®(US), Anexate®(EU)

View Details
Naloxone

Strength: 0.4 mg/mL in 1 mL/10 mL vials, 1 mg/mL in 2 mL prefilled syringes

Form: Intravenous (IV) injection/IM/SQ

Reference Brands: Narcan® (US); Narcan® (EU)

View Details

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

We use cookies to ensure you get the best experience. Learn more